RESOLUTION OF THE EXPERT COUNCIL: “ON THE PROSPECTS OF SOLVING THE ISSUE OF OBESITY AND THE NEED TO DEVELOP PERSONALIZED DIETARY CARE IN THE KEMEROVO REGION”

On December 19^th, 2024, the Council of Experts held a meeting with the support of “Geropharm” LLC, dedicated to solving the issue of obesity and the need to develop personalized dietary care for the population of the Kemerovo region.

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027–1050. doi: 10.1016/S0140-6736(23)02750-2.

2. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203-234. doi: 10.1016/S0140-6736(23)01301-6.

3. Tsygankova D.P., Bazdyrev E.D., Nakhratova O.V., Tsenter I.M., Gaziev T.F., Indukaeva E.V., Artamonova G.V., Barbarash O.L. Sex and age specificities of the dynamics of anthropometric indicators characterizing obesity (according to a prospective epidemiological research). Acta Biomedica Scientifica. 2023;8(6):204-211. doi: 10.29413/ABS.2023-8.6.20 (In Russian)

4. Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16(1):6 doi: 10.1186/s13098-023-01233-4.

5. Zhernakova Y.V., Zheleznova E.A., Chazova I.E., Oshchepkova E.V., Dolgusheva Y.A., Yarovaya E.B., Blinova N.V., Orlovsky A.A., Konosova I.D., Shalnova S.A., Rotar’ O.P., Konradi A.O., Shlyakhto E.V., Boytsov S.A. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study - ESSE-RF. Terapevticheskii arkhiv. 2018;90(10):14-22. (In Russian)

6. Bondareva E.A., Troshina E.A. Obesity. Reasons, features and prospects. Obesity and metabolism. 2024;21(2):174-187. doi: 10.14341/omet13055 (In Russian)

7. Rubrikator klinicheskih rekomendacij. Available at: https://cr.minzdrav.gov.ru/preview-cr/28_3 (accessed 05.03.2025) (In Russian)

8. Lingvay I., Brown-Frandsen K., Colhoun H.M., Deanfield J., Emerson S.S., Esbjerg S., Hardt-Lindberg S., Hovingh G.K., Kahn S.E., Kushner R.F., Lincoff A.M., Marso S.P., Fries T.M., Plutzky J., Ryan D.H.; SELECT Study Group. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023;31(1):111-122. doi: 10.1002/oby.23621.

9. Deanfield J., Verma S., Scirica B.M., Kahn S.E., Emerson S.S., Ryan D., Lingvay I., Colhoun H.M., Plutzky J., Kosiborod M.N., Hovingh G.K., Hardt-Lindberg S., Frenkel O., Weeke P.E., Rasmussen S., Goudev A., Lang C.C., Urina-Triana M., Pietilä M., Lincoff A.M.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024;404:773-86. doi: 10.1016/S0140-6736(24)01498-3.